Mirum says brelovitug hits primary endpoint in Phase 3 AZURE-4 trial for hepatitis delta
Mirum Pharmaceuticals disclosed topline results and new long-term data on the investigational antibody, with a BLA submission planned for early 2027.
SEC filing
7 stories
Mirum Pharmaceuticals disclosed topline results and new long-term data on the investigational antibody, with a BLA submission planned for early 2027.
SEC filing
Mirum launched ATEBRIOZ in FOP and posted positive results across ATEBRIOZ, LIVMARLI and brelovitug studies while lifting full-year product sales guidance.
SEC filing
Mirum plans an sNDA in the first half of 2027 to expand ATEBRIOZ's label to children aged 6 to under 12 with fibrodysplasia ossificans progressiva.
SEC filing
Mirum said the study hit its main goal and all five secondary measures, and plans a US filing in the first half of 2027.
SEC filing
Mirum disclosed FDA approval of Atebrioz for fibrodysplasia ossificans progressiva and positive Phase 3 AZURE-1 results for brelovitug in hepatitis delta, per a September 28, 2026 filing.
SEC filing
Mirum Pharmaceuticals disclosed a Chief Medical Officer transition, with Myers' start and Quan's separation both described as expected rather than final.
SEC filing